New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

World Cancer Day also marks the start of the ‘United by Unique’ campaign, which seeks to highlight how each person’s journey ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...